Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-25-059573
Filing Date
2025-04-29
Accepted
2025-04-29 07:41:02
Documents
8
Period of Report
2025-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A 2025_pyxs-14a.htm DEF 14A 1017545
2 GRAPHIC img179289491_0.jpg GRAPHIC 29935
3 GRAPHIC img179289491_1.jpg GRAPHIC 17889
4 GRAPHIC img179289491_2.jpg GRAPHIC 41024
5 GRAPHIC img179289491_3.jpg GRAPHIC 347782
6 GRAPHIC img179289491_4.jpg GRAPHIC 17889
7 GRAPHIC img179289491_5.jpg GRAPHIC 687026
8 GRAPHIC img179289491_6.jpg GRAPHIC 374122
  Complete submission text file 0000950170-25-059573.txt   3105802
Mailing Address 321 HARRISON AVENUE BOSTON MA 02118
Business Address 321 HARRISON AVENUE BOSTON MA 02118 (617) 221-9059
Pyxis Oncology, Inc. (Filer) CIK: 0001782223 (see all company filings)

EIN.: 831160910 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40881 | Film No.: 25882701
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)